Cyplasin Biomedical Engages Rathbourne Mercantile and Secures LOI for Equity
Financing

EDMONTON, Nov. 5 /CNW/ - Cyplasin Biomedical (CPBM: OTCBB and XYI1:FRA) is a product-oriented, specialty pharmaceutical company focused on developing products for the multi-billion dollar hepatitis C virus (HCV) market. The Company is pleased to announce that it has engaged the services of Rathbourne Mercantile to develop strategic and corporate  business partners and has received a subsequent Letter of Intent from a third party for an equity financing to fund the Company's operations and product development programs.

The Company engaged Rathbourne Mercantile to secure  strategic, corporate and financing partners and has subsequently received an LOI from an external financing source. Cyplasin CEO Garth Likes commented, "We are pleased to have secured this arrangement with Rathbourne and the external funding group as it puts into place the needed next step in our overall financial and corporate progress. We look forward in working closely with Rathbourne as we continue to grow, and execute on our previously announced C-Virin and C-Pegferon therapeutic product development program. We hope to be able to announce completion of this transaction in the near future as we move to final terms. As well we are moving forward in expanding our distribution channels and hope to be able to complete these talks in the near future.

Mr. Likes went on to comment, "I would also like to direct interested persons to our website at www.c-pharma.net and to sign up for our news letter which will be available on a quarterly basis."

ABOUT CYPLASIN: http://www.c-pharma.net/

Cyplasin Biomedical is a publically-traded specialty pharmaceutical company (OTCBB:CPBM ) with headquarters in Edmonton, Alberta. Cyplasin has amassed a portfolio of key products for the treatment and prevention of HCV infection, which affects over 4 million people in the U.S. and several hundred million people worldwide.

Cyplasin's technology encompasses the use of recombinant technology to manufacture recombinant cytokines and virus like particles (VLPs). VLPs can be engineered to incorporate various viral and non-viral antigens for use as vaccines against many different types of targets such as hepatitis C. Cyplasin is using the technology to develop a hepatitis C vaccine ( C- Vaxin) to prevent hepatitis C viral infection. The Company is also pursuing a revenue generation strategy by commercializing highly profitable therapeutic drugs (C-Virin & C-Pegferon) for use in the hepatitis C market.

About Rathbourne Mercantile

Rathbourne Mercantile provides independent and objective international corporate finance advice on a range of business transactions. Rathbourne Mercantile's International Corporate Finance consultants offer international financial opinions and advice to assist clients in international planning, negotiating, restructuring, M&A, financing transactions and listings in Europe, Canada and Asia.

• Working with finance executives in the formation, structuring and implementation of a international financing strategy
• Assisting with the development of appropriate funding alternatives and with the development of a global strategy for negotiating with debt investors and equity underwriters
• Providing international advice for IPO's, equity placements and rights issues, refinancing and new debt raisings and assistance with structuring, arranging and procurement
• International assistance with the assessment of capital structure, including determination of 'headroom capacity' and 'debt capacity', and helping to provide the optimal capital mix.

Forward Looking Statements This news release contains "forward-looking statements", as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this current report which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainty offinancial estimates and projections, the competitive and regulatory environments, stock market conditions, unforeseen technical difficulties and our ongoing ability to operate a business and obtain financing. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differfrom those projected in the forward-looking statements.

Although we believe that our beliefs, plans, expectations and intentions contained in this current report are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our quarterly reports on Form 10-Q and our other periodic reports filed from time-to-time with the Securities and Exchange Commission pursuant to the Securities Exchange Act.

For further information:

Visit our new websitewww.c-pharma.netor contact:
Mr. Garth Likes, President/CEO,[email protected],
Ph: [phone]